Related by context. All words. (Click for frequent words.) 66 successfully commercialize Iluvien 65 ACTEMRA TM 65 CCR9 antagonist 64 Zemplar Capsules 64 HuMax EGFr 63 Cimzia TM 63 Aeolus Pharmaceuticals Announces 63 QVAR 62 CIMZIA ™ 62 vidofludimus 62 AeroLEF TM 62 faropenem 62 Virulizin ® 62 HQK 61 CRMD# 61 novel oral anticoagulant 61 Cand5 61 cannabinor 61 TOLAMBA 61 UPLYSO 61 Panzem R NCD 61 Relivar 61 CCX# 61 Genz # 60 CRLX# 60 Phase 1a clinical 60 IPL# 60 Ophena 60 Dextofisopam 60 Tyrima 60 cystinosis patients 60 Phase 1b trial 60 canakinumab 60 Vidofludimus 60 ularitide 60 dasatinib Sprycel 60 oral ridaforolimus 60 Q#IR 60 liposomal formulation 60 Neuromodulation System 59 novel VDA molecule 59 PDE4 inhibitor 59 ruxolitinib 59 CINOD 59 HGS# 59 EVIZON ™ 59 rxRNA 59 tubulin inhibitor 59 CAPHOSOL 59 RLY# 59 HCD# [002] 59 phase IIa clinical 59 Valortim ® 59 SNT MC# 59 EDEMA3 58 PyratineXR 58 Zyclara 58 OncoVEX 58 GAMMAGARD 58 favorable pharmacokinetic profile 58 GLP toxicology studies 58 HGS ETR2 58 alicaforsen enema 58 adenosine injection 58 clevidipine 58 Cipralex ® 58 XOPENEX Inhalation Solution 58 Tracleer R 58 sargramostim 58 TransVax tm 58 INT# [002] 58 novel nucleoside analog 58 bortezomib Velcade 58 sitaxsentan 58 IIa trial 58 non metastatic osteosarcoma 58 elagolix 58 AIR# [001] 58 Flutiform TM 58 inhaled AAT 57 Spiegelmer ® 57 fosbretabulin 57 Pharmacokinetic parameters 57 OMAPRO 57 ADAGIO study 57 lumiliximab 57 NasalFent 57 GRN# 57 PROCHYMAL 57 Plicera 57 ulimorelin 57 PEGPH# 57 OvaRex R 57 epinastine 57 mg/m2 cohort 57 Anticalin R 57 JAK inhibitors 57 Hedgehog antagonist 57 BCR ABL inhibitors 57 vascular disrupting agent 57 Orally administered 57 Squalamine 57 pharmacodynamic PD 57 MEND CABG II 57 indibulin 57 ARIKACE ™ 57 analgesic efficacy 57 viral kinetics 57 pharmacokinetic equivalence 57 Zavesca r 57 XmAb# 57 immune modulating 57 Maximum Tolerated Dose 57 xanthine oxidase inhibitor 57 O PPDS 56 preclinical efficacy 56 samalizumab 56 Targretin capsules 56 Solasia 56 LHRH antagonists 56 dose proportionality 56 Pyridorin 56 Gleevec resistant 56 pharmacokinetic PK profile 56 novel histone deacetylase 56 Harry Palmin President 56 PSMA ADC 56 Ultrafast Insulin 56 Discovery Labs KL4 56 interferon beta therapy 56 REMINYL ® 56 tipranavir r 56 tecarfarin 56 REMUNE R 56 BEXXAR 56 cMET 56 oral prednisolone 56 Afatinib 56 Cinquil 56 hematological tumors 56 Tarsa oral calcitonin 56 JAK#/JAK# inhibitor CYT# 56 Thorough QT 56 MERLIN TIMI 56 ENMD # 56 SURFAXIN r 56 Multiple Ascending Dose 56 demonstrated clinically meaningful 56 JAK2 inhibitor 56 deforolimus 56 Phase III confirmatory 55 Tarvacin TM 55 cediranib 55 GAP #B# 55 Technosphere Insulin 55 TNF alpha inhibitor 55 imexon 55 CIP TRAMADOL ER 55 HCV protease inhibitors 55 Evoltra 55 Proellex TM 55 bevasiranib 55 Lixivaptan 55 brivaracetam 55 ASONEP 55 Tesmilifene 55 ANAVEX #-# [001] 55 BrachySil TM 55 ACZ# 55 OvaRex 55 ATL# [001] 55 Optiquel ™ 55 neuroprotective properties 55 Firazyr 55 BenzEFoam 55 IIa trials 55 small molecule tyrosine 55 trastuzumab emtansine T DM1 55 selective modulator 55 immatics 55 LB# [003] 55 opioid bowel dysfunction 55 ® natalizumab 55 AMPK activators 55 antiviral efficacy 55 pharmacodynamics PD 55 Aplidin 55 Xerecept 55 MoxDuo 55 ALN HTT 54 Phase IIa trials 54 DACH platinum 54 initiate Phase 1b 54 maximally tolerated 54 favorable pharmacokinetic 54 potency selectivity 54 PSN# [001] 54 rhFVIIa 54 EGS# 54 Phase #b/#a 54 investigational antiplatelet 54 clonidine hydrochloride 54 RH1 54 elvucitabine 54 Solorel TM 54 preclinically 54 Akt inhibitor 54 vascular disrupting agents 54 isoform selective 54 lenalidomide dexamethasone 54 omacetaxine mepesuccinate 54 TKM PLK1 54 Trofex 54 schizophrenia CIAS 54 Tekmira SNALP technology 54 commented Alexis Borisy 54 MIST II 54 Aerosurf 54 eTag assays 54 SLx 54 Potelligent Technology 54 TriRima 54 antiangiogenic activity 54 RSD# 54 rindopepimut 54 MYLOTARG 54 Pitavastatin 54 confirmatory clinical 54 injectable formulations 54 initiate Phase 2b 54 refractory CLL 54 Removab 54 HIV coinfected 54 Pharmacokinetic studies 54 human microdosing 54 INTEGRILIN 54 relapsed ALL 53 RenalGuard System TM 53 PRESEPT 53 MICARDIS ® 53 OnDose 53 BNC# 53 enoximone 53 Aurora kinase inhibitor 53 PROMACTA ® 53 Glypromate 53 QuadraSphere 53 VEGF inhibitor 53 CCR5 antagonist 53 ALV# 53 intranasal insulin 53 symptomatic paroxysmal AF 53 MET amplification 53 ® pioglitazone HCl 53 nanopharmaceutical 53 anti arrhythmic 53 PROSTVAC ® 53 hematological parameters 53 Platinum Chromium 53 ganaxolone 53 CLL8 53 oxaliplatin Eloxatin 53 relapsed SCLC 53 anti angiogenic agent 53 Zelnorm Zelmac 53 retaspimycin 53 TLR antagonists 53 XL# SAR# 53 Hedgehog inhibitor 53 gallium containing 53 systemic RNAi 53 DP b# 53 chimeric monoclonal antibody 53 NEVO ™ 53 efficacy endpoint 53 Spheramine 52 initiate Phase IIa 52 orBec 52 CTCE 52 Urocidin 52 CobaCyte 52 FBPase 52 VIBEX MTX 52 NEUGENE antisense 52 clinical pharmacology studies 52 Zavesca ® 52 zotarolimus 52 CytoFabTM 52 Toraymyxin TM 52 HuCAL antibodies 52 pediatric acute lymphoblastic 52 TRX1 52 Anticalin 52 ABSORB trial 52 hA# 52 oxidative stress inducer 52 randomized Phase 2b 52 Angiox ® 52 Eligen R Technology 52 convenient dosing regimens 52 A3 adenosine receptor 52 NeuVax 52 STX# 52 MET inhibitor 52 anti leukemic 52 Eligen R B# 52 targeting PCSK9 52 mucosal healing 52 SERCA2a 52 Kevetrin ™ 52 oral treprostinil 52 BLA filing 52 mTOR inhibitors 52 R roscovitine 52 cytokine refractory 52 Fc fusion protein 52 EOquin 52 recurrent glioblastoma 52 drug eluting stent DES 52 MAXY alpha 52 mTOR mammalian target 52 TAKSTA 52 Zevalin consolidation 52 punctal plug 52 doxorubicin docetaxel 52 Bacille Calmette Guérin BCG 52 photoprotective drug 52 K ras mutations 52 TroVax ® 52 B. Lynne Parshall 52 naltrexone SR 52 Combination therapy 52 peptide conjugated 51 PDE4 inhibitors 51 Retisert 51 XERECEPT R 51 DCCR 51 pharmacological chaperone 51 pharmacokinetics PK 51 taxane derivative 51 Provent Therapy 51 Alequel ™ 51 AERx iDMS 51 PEP# [003] 51 BRAF inhibitors 51 favorable tolerability 51 Antioxidant supplements 51 Ventavis ® 51 PLAVIX ® 51 glucagon receptor 51 TLR agonists 51 CB2 selective 51 Isolagen Process 51 PI3K/mTOR 51 Therapeutic Diagnostics 51 bioequivalency 51 FOLFOX regimen 51 AIM HIGH 51 BioMatrix TM 51 intranasal ketamine 51 bucindolol 51 antiviral potency 51 imatinib therapy 51 Arsenic trioxide 51 Hsp# inhibition 51 vation TA 51 Preclinical studies 51 Loretta M. Itri 51 Protelos 51 levodopa carbidopa 51 QTinno TM 51 pharmacokinetic pharmacodynamic 51 darunavir r 51 PROactive study 50 NNRTI resistant virus 50 punctal plug delivery 50 Sensipar 50 SNALP formulations 50 Carotid endarterectomy 50 selectively inhibited 50 Microdosing 50 haematological cancers 50 subcutaneous immunoglobulin 50 GnRH antagonist 50 QTinno 50 VIDAZA ® 50 SIMPADICO 50 liposome formulation 50 inhibits VEGF 50 ischemic tissues 50 MorphoSys proprietary 50 JAK2 inhibitors 50 synthase TS 50 Voraxaze ™ 50 dose escalation Phase 50 oblimersen 50 Thorough QT TQT 50 histone deacetylase HDAC 50 Dr. Bahcall 50 XR NTX 50 VITAL Trial 50 Hemopurifier ® 50 circulating endothelial cells 50 PREVU 50 Src inhibitors 50 refractory colorectal cancer 50 generation FBPase inhibitor 50 TrialMaster 49 MYTHOS trial 49 antiangiogenic therapy 49 BeneFIX 49 Endeavor DES 49 TAXUS Express Stent 49 anti fibrotic 49 HYLENEX recombinant 49 opioid analgesia 49 ESTRASORB 49 genotypic resistance 49 immunostimulatory effects 49 UVIDEM 49 QT QTc 49 antisense inhibition 49 MVA BN 49 antidepressant efficacy 49 intestinal mucosal 49 InterfeRx 49 gonadotrophin releasing hormone GnRH 49 effector function 49 Vectibix panitumumab 49 MetAP2 49 OvaRex MAb 49 mTOR inhibition 49 DAPT 49 allergic airway inflammation 49 selective kinase inhibitors 49 cardioprotective effects 49 triphendiol 49 JAK#/JAK# 49 everolimus eluting stents 49 selective agonist 49 Resolute DES 49 stavudine d4T 49 Randomized trials 49 2 methoxyestradiol #ME# 49 Dose escalation 48 peak plasma concentrations 48 statistically significant efficacy 48 PRESEPT study 48 MetMAb 48 antiapoptotic 48 CCR2 48 tropism testing 48 IgG1 antibody 48 Mycophenolate mofetil 48 unimaginable savagery thousands 48 Post hoc 48 fludarabine cyclophosphamide 48 TAXUS TM 48 immunomodulation 48 FAMPYRA 48 nanomolar potency 48 aEURoeThis 48 Vascugel R 48 Lipid lowering 48 potently inhibits 48 Angioblast 48 Phase #/#a clinical 48 NTCD 48 fibrotic disease 48 Fracture Intervention Trial 48 docetaxel emulsion 48 antihypertensive therapies 48 thymidylate synthase TS 48 Diamyd r vaccine 48 siRNAs targeting 48 VLP vaccines 48 multicenter clinical trials 48 EGFR mutation status 47 aurora kinase inhibitor 47 antiangiogenic agent 47 GENASIS trial 47 aptamer therapeutics 47 GDIR 47 peptidomimetic 47 IgG1 antibodies 47 NKX#.# 47 microdose 47 HalcyGen 47 MCOT TM 47 Phospha E 47 biomarker assay 47 surgically resectable 47 selectively binds 47 NeuroSolutions 47 onset AF 47 plasminogen activators 47 mCRPC 47 Modrenal 47 kinase inhibition 47 SCENESSE 47 bupropion HCl 47 ADVEXIN therapy 47 siRNA mediated 46 DepoVax ™ 46 eClinical suite 46 vivo potency 46 Garnet Biotherapeutics 46 glioblastoma tumors 46 Nabriva 46 mGluR5 inhibition 46 NurOwn ™ 46 citicoline 46 cortical stimulation 46 Biomerk Tumorgrafts 46 IFN alpha 2b 46 radiographic outcomes 46 clinically meaningful 46 intravenous CK # 46 VaxImmune 46 Tumor shrinkage 46 delipidation 46 radiolabeled 46 Activated Checkpoint Therapy 45 antiandrogen 45 PI3 kinase inhibitors 45 durable remissions 45 5 HT2C receptor 45 trans retinoic acid ATRA 45 PTHrP 45 Randomised controlled trials 45 Rubicon Filter 45 RONDEL 45 Pharmacokinetic analyzes 45 paraprotein 45 botanically derived 45 Arisaph 45 ConclusionThis 45 tropism assay 45 outlicensing 45 Nav#.# 45 adenosine deaminase 45 JM Dutton adds 45 plasma renin activity 45 Epidemiologic studies 45 Trofile assay 45 recombinant antithrombin product 45 NNRTI resistance 45 IL #E 45 Option IVC Filter 45 Septin 9 biomarker 45 ION Stent 45 K DOQI guidelines 45 chromosome #p# [002] 44 liver histology 44 predialysis 44 ICSs 44 Nick Leschly 44 OrCel 44 Intergroup Exemestane Study 44 IVTA 44 Myoblast Program 44 Adverse events 44 prostatic tissue 44 TRIST study 44 selective agonists 44 lamivudine resistant 44 misfolded SOD1 44 prognostic indicators 44 carcinoembryonic antigen 44 PathFinderTG 44 #mg BID [002] 44 epigenetic biomarkers 44 Subgroup analysis 44 recombinant albumin 44 Virologic failure 44 ImmuneY2 44 antibody humanization 44 dose dependently 44 taxane therapy 43 serotonin synthesis 43 nucleoside naive patients 43 Mr. Feldenkreis 43 Pentraxin 2 43 Postoperatively 43 somatostatin receptor 43 debulking surgery 43 postprandial hyperglycemia 43 radiosensitivity 43 folate receptor 43 CHAMPION PLATFORM 43 Johan Löf 43 therapeutically relevant 43 SNP rs# [002] 43 phage display technology 43 TLE3 43 genotoxicity 43 drug elution 43 genotype phenotype 43 mediated inhibition 43 LV dysfunction 43 human monoclonal antibody 43 HERmark assay 43 HYC# 43 attain statistical significance 43 HuCAL 43 TGR5 43 TriGrid ™ 43 labetuzumab 43 homocysteine assay 43 IL 1ß 43 intact parathyroid hormone 43 VIDAZA azacitidine 43 unmeasured confounding 43 atherogenic lipids 43 alpha7 NNR 43 patient subpopulations 42 Subgroup analyzes 42 Randomized clinical trials 42 Beyondie 42 Mr. Owusu Akyaw 42 CXCR7 42 lipid nanoparticles LNPs 42 gastric stasis 42 mucosal immune responses 42 Dickersin 42 Fc receptor 42 Oncotype DX Recurrence Score 42 resVida ® 42 fluorescence polarization 42 aza anthracenedione molecular 42 AnorMED expectation 42 mutated K ras 42 cardioprotection 42 chemosensitivity 42 potent stimulator 42 EPC# 42 liver fibrosis cirrhosis 42 adjuvant AS# 42 Lyn kinase 42 Observational studies 41 fructosamine 41 c myc gene 41 pressure natriuresis 41 p# Shc 41 SIRT1 enzyme 41 proprietary phage display 41 Ph3 41 pre malignant lesions 41 MGMT methylation 41 serum lipid 41 rechallenge 41 peritoneal carcinomatosis 41 periprocedural MI 41 Goodbody Stockbrokers adds 41 OGG1 41 biosimilar insulin 40 estrogen receptor beta 40 IntroductionThe 40 pituitary hormone 40 EB# ® 40 PolyNovo 40 Toric IOL 40 urodynamic 40 Cognitive impairment 40 Phase Ib IIa clinical 40 Previous epidemiological studies 40 FSH receptor 40 lesional 40 JPI JJB 40 rituximab monotherapy 40 CTx 40 human IgG2 monoclonal 39 Trial ALLHAT 39 TAXUS stents 39 Prospectively 39 QSAR models 39 ZFP 39 norepinephrine reuptake inhibition 39 ionophore 39 Sensitivity analyzes 39 inflatable penile prosthesis 39 OvPlex ™ 39 ERb 39 melatonin receptor 39 murine mouse 38 hESC derived cells 38 reproducibly 38 Essential Medicines List 38 Importantly 38 SpHb monitoring 37 pharmacophore 37 Haib Project 37 gene rearrangements 37 BCCs 37 Perkinamine 37 Mechanistic studies 36 Clinical trials 36 Handcamp property 36 MIF gene 36 osteogenic differentiation 36 prospectively 36 Inaddition 36 phosphorylase 35 putative biomarkers 35 DNA demethylation 35 ERa 35 multivariate regression 35 Logistic regression analyzes 35 preterm lamb 35 Freund adjuvant 35 coexpression 35 Webelieve 35 Epidemiological studies 35 Nrf2 gene 34 Dr. Urnovitz 34 HGD 34 antigenic peptides 34 mitigant 33 EPS accretion 33 Dr. Gapontsev 33 Printelligence TM 33 asignificant 32 target lesion revascularizations 31 LV systolic function 31 TSX VENTURE EEL FRANKFURT 29 stepwise fashion 29 Roseby Copper Project 28 commercially producible 28 axon outgrowth 27 Qualitatively 27 Reassuringly 27 Empirically 27 Previous studies 26 Consistent 26 Longer term 25 Overall 25 Most importantly 25 Operationally 25 Secondarily 25 Additionally 24 Further 24 Empirical evidence 24 Cre recombinase 23 significant 23 Encouragingly 23 Domestically 23 Recent 22 Cumulatively 22 Furthermore 22 â € œWe 22 Significantly 22 Concurrently 21 Strategically 21 Upon completion 21 Subsequent 21 Correspondingly 21 Our 20 Externally 20 â € œOur 20 Early indications 20 Critically 19 â € œThis 19 Worryingly 19 Collectively 19 Equally 19 Therefore 19 Moreover 18 furthermore 18 We 18 Taken together 18 Accordingly 18 Specifically 18 None 18 Nationally 18 Nevertheless 17 More importantly 17 Separately 17 Approximately 17 â € œWhile 17 Complementing 16 These 16 Anecdotal evidence 16 Previously 16 Whilst 16 Consequently 16 Consequentially 16 Intuitively 15 Anecdotally 15 Broadly 15 Generally speaking 15 Alarmingly 15 This 15 Nonetheless 15 Clearly 15 Internally 15 Once 14 Numerous 14 Finally 14 Impressively 14 Lastly 14 Fundamentally 14 Notably 14 Coupled 14 Strikingly 14 Many 14 Initially 14 Given 14 Primarily 14 Throughout 13 Historically 13 During 13 Neither 13 Unquestionably 13 Generally 13 Nor 13 Both 13 Such 13 Contrarily 13 Plainly 13 Principally 13 Most 13 Using 12 However 12 Assuming 12 Thus 12 Although 12 Only 12 Currently 12 Certainly 12 Regretfully 12 Ominously 12 Conceptually 12 Alternatively 12 Notwithstanding 12 Anecdotal evidence suggests 12 Ultimately 12 Hopefully 12 Crucially 12 Several 11 Quite simply 11 Simultaneously 11 Utilising 11 Presently 11 Until 11 although 11 Realistically 11 Fortunately 11 Firstly 11 Some 11 Paradoxically 11 Fourthly 11 While 11 Conversely 11 Luckily 10 Recognising 10 It 10 Hence 10 Altogether 10 Regrettably 10 Because 10 Surprisingly 10 Thankfully 10 Yet 10 Futhermore 10 Needless 10 Disturbingly 10 Having 10 Secondly 10 Roughly 10 Frankly 10 Recently 10 Granted 10 Thirdly 9 whereby 9 Obviously 9 Earlier 9 More worryingly 9 Similar 9 Broadly speaking 9 If 9 Happily 9 Remarkably 9 The 9 Even 9 As 9 In 9 Somewhat surprisingly 9 Despite 9 Considering 9 Comparatively 8 Though 8 Whichever 8 Inasmuch 8 They 8 Unfortunately 8 Either 8 Intriguingly 8 Each 8 Typically 8 Ideally 8 Knowing 8 Tragically 8 Indeed 7 Undoubtedly 7 Thereafter 7 Perversely 7 Sure 7 Gradually 7 Regardless 7 Interestingly 7 Admittedly 7 Miraculously 7 So 7 Traditionally 7 Irrespective 7 Logically 7 Subsequently 7 Suffice 7 Arguably 7 And 7 Perhaps 7 Alongside 7 Disappointingly 7 Noting 6 Similarly 6 Along 6 But 6 Theoretically 6 He 6 Usually 6 Since 6 Sadly 6 Unlike 6 Amazingly 6 Unsurprisingly 6 Of course 6 Tellingly 6 Otherwise 6 Whether 6 Namely 6 Also 6 Unless 5 That 5 Not surprisingly 5 Evidently 5 Actually 5 When 5 Whatever 5 Naturally 5 whereas 5 Whenever 5 which 5 Somehow 5 Normally 5 Likewise 4 Eventually 4 Now 4 Albeit 4 Incredibly 4 Inexplicably 4 Invariably 4 Conveniently 4 Presuming 4 Ordinarily 4 Mercifully 4 Predictably 3 Surely 3 Technically 3 Doubtless 3 Strangely enough 3 Besides 3 Meanwhile 3 Strangely 3 Alas 3 Basically 3 Meantime 2 Whereas 2 Essentially 2 Astonishingly 2 Infact 2 Funnily enough 2 Understandably 2 Presumably 1 Strictly speaking 1 Supposedly 1 Oddly 1 Apparently 1 Then 1 Inevitably 1 Not coincidentally 1 Curiously 0 Instead 0 Bizarrely 0 Afterall 0 Oddly enough -1 Ironically -1 Never mind -2 Incidentally -2 Coincidentally